{"id":875028,"date":"2025-08-13T08:03:24","date_gmt":"2025-08-13T12:03:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/"},"modified":"2025-08-13T08:03:24","modified_gmt":"2025-08-13T12:03:24","slug":"bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/","title":{"rendered":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales"},"content":{"rendered":"

<\/p>\n

bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales<\/b><\/p>\n

July Test Volume Surges 72% Over Prior Monthly Average<\/b><\/p>\n

SAN ANTONIO–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW)<\/b>,a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship product, CyPath\u00ae Lung<\/b><\/a>, a noninvasive diagnostic for early-stage lung cancer.<\/p>\n

\nFollowing a record-setting second quarter, the Company\u2019s third quarter started strong. Completed tests in July represent a 72% increase over the previous monthly average for the first six months of 2025. The upward trend reflects back-to-back record monthly sales in June and July. The Company reaffirmed its forecast of 3X year-over-year revenues for CyPath\u00ae Lung.<\/p>\n

\n\u201cCyPath\u00ae Lung\u2019s ability to detect lung cancer at its earliest stage, as evidenced by recent case studies, has fueled the growing adoption of CyPath\u00ae Lung across a growing base of clinicians, which is driving momentum in the marketplace,\u201d said Maria Zannes, President and CEO of bioAffinity Technologies. \u201cThis early Q3 surge is especially encouraging because it reflects increasing awareness and trust in our technology\u2019s ability to support earlier, more accurate diagnosis of lung cancer, especially for high-risk patients with indeterminate lung nodules.\u201d<\/p>\n

\n\u201cPhysician demand, payer coverage, and patient access continue to build a strong foundation for long-term revenue growth,\u201d said J. Michael Edwards, bioAffinity Technologies\u2019 Chief Financial Officer. \u201cThe success of our pilot marketing program in Texas, which has approximately 6% of the total number of U.S. pulmonologists, has demonstrated that our approach to the medical community is sound and effective. We are prepared to meet increased demand as we implement our strategy to enter additional key markets, including our expansion in the Mid-Atlantic region and the Veterans Administration healthcare system.\u201d<\/p>\n

\nThe Company recently released three patient case studies in which CyPath\u00ae Lung detected Stage 1A cancer after standard imaging, risk calculator models and serum marker tests indicated the nodules were likely benign. The patients\u2019 final pathology reports confirmed Stage 1A for adenocarcinoma, a neuroendocrine tumor and mucinous adenocarcinoma, respectively. The latter two cancers are often difficult to detect with imaging and bronchoscopy alone.<\/p>\n

\n\u201cThe key to improving survival rates for lung cancer is early detection. When lung cancer is found at Stage 1A, there are many curative options,\u201d said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. \u201cPhysicians are finding that a CyPath\u00ae Lung test result \u2013 whether it is positive or negative for cancer \u2013 can better inform shared decision making between doctor and patient and ease anxiety about appropriate next steps.\u201d<\/p>\n

About CyPath\u00ae Lung<\/b><\/p>\n

\nCyPath\u00ae Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results<\/a> demonstrated that CyPath\u00ae Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com<\/a>.<\/p>\n

About bioAffinity Technologies, Inc.<\/b><\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the increase in the number of physician offices signed, positioning the Company for continued growth in 2025; the Company having the science, strategy and leadership to shape the future of lung cancer diagnostics; the ability of CyPath\u00ae Lung to indicate a high probability of lung cancer; the benefits of adding CyPath\u00ae Lung to the standard of care for evaluating indeterminate lung nodules; and CyPath\u00ae Lung providing clarity when imaging and risk models are inconclusive and when other adjuvant diagnostics are contraindicated. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the increase in the number of physician offices signed, positioning the Company for continued growth in 2025; the Company having the science, strategy and leadership to shape the future of lung cancer diagnostics; the ability of CyPath\u00ae Lung to indicate a high probability of lung cancer; the benefits of adding CyPath\u00ae Lung to the standard of care for evaluating indeterminate lung nodules; and CyPath\u00ae Lung providing clarity when imaging and risk models are inconclusive and when other adjuvant diagnostics are contraindicated, and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250807842867\/en\/<\/a><\/span><\/p>\n

bioAffinity Technologies
\n<\/b>
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com<\/a><\/p>\n

Investor Relations
\n<\/b>
Dave Gentry
\n
RedChip Companies Inc.
\n
1-800-RED-CHIP (733-2447) or 407-491-4498
\n
BIAF@redchip.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Health Technology Radiology Research Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship product, CyPath\u00ae Lung, a noninvasive diagnostic for early-stage lung cancer. Following a record-setting second quarter, the Company\u2019s third quarter started strong. Completed tests in July represent a 72% increase over the previous monthly average for the first six months of 2025. The upward trend reflects back-to-back record monthly sales in June and July. The Company reaffirmed its forecast of 3X year-over-year revenues for CyPath\u00ae Lung. \u201cCyPath\u00ae Lung\u2019s ability to detect lung cancer … <\/p>\n

Continue reading “bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-875028","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nbioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship product, CyPath\u00ae Lung, a noninvasive diagnostic for early-stage lung cancer. Following a record-setting second quarter, the Company\u2019s third quarter started strong. Completed tests in July represent a 72% increase over the previous monthly average for the first six months of 2025. The upward trend reflects back-to-back record monthly sales in June and July. The Company reaffirmed its forecast of 3X year-over-year revenues for CyPath\u00ae Lung. \u201cCyPath\u00ae Lung\u2019s ability to detect lung cancer … Continue reading "bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-13T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales\",\"datePublished\":\"2025-08-13T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/\"},\"wordCount\":1087,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/\",\"name\":\"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-08-13T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk","og_description":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship product, CyPath\u00ae Lung, a noninvasive diagnostic for early-stage lung cancer. Following a record-setting second quarter, the Company\u2019s third quarter started strong. Completed tests in July represent a 72% increase over the previous monthly average for the first six months of 2025. The upward trend reflects back-to-back record monthly sales in June and July. The Company reaffirmed its forecast of 3X year-over-year revenues for CyPath\u00ae Lung. \u201cCyPath\u00ae Lung\u2019s ability to detect lung cancer … Continue reading \"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-13T12:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales","datePublished":"2025-08-13T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/"},"wordCount":1087,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/","name":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-08-13T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250807842867r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-reports-accelerating-growth-in-cypath-lung-test-sales\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Reports Accelerating Growth in CyPath\u00ae Lung Test Sales"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/875028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=875028"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/875028\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=875028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=875028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=875028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}